Tempus AI EVP sells shares worth $531,918

Tempus AI's EVP Erik Phelps sold 8,415 shares for approximately $531,918 to cover tax obligations amid a recent stock decline of 9.53%. This sale follows positive news for Tempus AI, including a 75.4% year-over-year revenue increase in Q1, exceeding expectations, and strategic partnerships with Verastem Oncology and Boehringer Ingelheim. Morgan Stanley raised its price target to $65, citing a significant AstraZeneca contract and increased 2025 revenue guidance to $1.25 billion, reflecting an anticipated 80% growth.

Analysis

Tempus AI, Inc. (NASDAQ:TEM) experienced an insider sale by its Executive Vice President and Chief Administrative & Legal Officer, Erik Phelps, who sold 8,415 shares of Class A Common Stock on May 20, 2025, for approximately $531,918. This transaction, executed at prices between $63.21 and $63.70 per share, was a mandatory "sell to cover" action to satisfy tax withholding obligations from vested restricted stock units, leaving Phelps with 149,096 shares. This sale occurred amidst a 9.53% decline in TEM's stock price over the past week. Despite this short-term stock pressure, Tempus AI recently reported strong fundamental performance, with first-quarter revenue surging 75.4% year-over-year to $255.7 million, surpassing analyst expectations of $248.5 million. Earnings per share were also slightly better than anticipated at -$0.24 versus a forecast of -$0.26. Strategically, Tempus AI has announced significant collaborations, including a partnership with Verastem Oncology to develop a companion diagnostic test and a multi-year alliance with Boehringer Ingelheim to advance cancer treatment research using Tempus's AI platform. Furthermore, Morgan Stanley raised its price target on TEM to $65 from $60, maintaining an Overweight rating, buoyed by the robust Q1 results and a substantial $200 million contract with AstraZeneca and the Pathos foundation. In light of these developments, Tempus AI increased its full-year 2025 revenue guidance to $1.25 billion, projecting an 80% year-over-year growth, underscoring its focus on AI, data infrastructure, and leadership in precision oncology.

Key Decisions for Investors

• Investors should weigh the recent 9.53% stock price decline and the technical nature of the insider sale against Tempus AI's strong Q1 financial results, including a 75.4% revenue increase and an upward revision of full-year 2025 revenue guidance to $1.25 billion.
• The strategic partnerships with Verastem, Boehringer Ingelheim, and the significant $200 million AstraZeneca contract present substantial growth catalysts, which should be monitored for execution and impact on future earnings.
• Given Morgan Stanley's increased price target of $65 and Overweight rating, coupled with the company's robust growth outlook, current share price levels may warrant consideration for long-term investors, while acknowledging potential near-term volatility indicated by the recent stock performance.